Bristol’s Sprycel To Launch “Within Days”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.